JP2022048153A5 - - Google Patents

Download PDF

Info

Publication number
JP2022048153A5
JP2022048153A5 JP2021213604A JP2021213604A JP2022048153A5 JP 2022048153 A5 JP2022048153 A5 JP 2022048153A5 JP 2021213604 A JP2021213604 A JP 2021213604A JP 2021213604 A JP2021213604 A JP 2021213604A JP 2022048153 A5 JP2022048153 A5 JP 2022048153A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid encoding
car
anticancer agent
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021213604A
Other languages
English (en)
Japanese (ja)
Other versions
JP7300763B2 (ja
JP2022048153A (ja
Filing date
Publication date
Priority claimed from JP2020048623A external-priority patent/JP7008350B2/ja
Application filed filed Critical
Publication of JP2022048153A publication Critical patent/JP2022048153A/ja
Publication of JP2022048153A5 publication Critical patent/JP2022048153A5/ja
Priority to JP2023097065A priority Critical patent/JP7527049B2/ja
Application granted granted Critical
Publication of JP7300763B2 publication Critical patent/JP7300763B2/ja
Priority to JP2024113188A priority patent/JP7755890B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021213604A 2014-10-09 2021-12-28 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 Active JP7300763B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023097065A JP7527049B2 (ja) 2014-10-09 2023-06-13 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
JP2024113188A JP7755890B2 (ja) 2014-10-09 2024-07-16 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014208200 2014-10-09
JP2014208200 2014-10-09
JP2020048623A JP7008350B2 (ja) 2014-10-09 2020-03-19 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020048623A Division JP7008350B2 (ja) 2014-10-09 2020-03-19 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023097065A Division JP7527049B2 (ja) 2014-10-09 2023-06-13 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞

Publications (3)

Publication Number Publication Date
JP2022048153A JP2022048153A (ja) 2022-03-25
JP2022048153A5 true JP2022048153A5 (OSRAM) 2022-09-20
JP7300763B2 JP7300763B2 (ja) 2023-06-30

Family

ID=55652864

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2016552830A Active JP6161098B2 (ja) 2014-10-09 2015-10-06 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
JP2017111736A Active JP6683990B2 (ja) 2014-10-09 2017-06-06 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
JP2020048623A Active JP7008350B2 (ja) 2014-10-09 2020-03-19 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
JP2021213604A Active JP7300763B2 (ja) 2014-10-09 2021-12-28 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
JP2023097065A Active JP7527049B2 (ja) 2014-10-09 2023-06-13 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
JP2024113188A Active JP7755890B2 (ja) 2014-10-09 2024-07-16 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2016552830A Active JP6161098B2 (ja) 2014-10-09 2015-10-06 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
JP2017111736A Active JP6683990B2 (ja) 2014-10-09 2017-06-06 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
JP2020048623A Active JP7008350B2 (ja) 2014-10-09 2020-03-19 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023097065A Active JP7527049B2 (ja) 2014-10-09 2023-06-13 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
JP2024113188A Active JP7755890B2 (ja) 2014-10-09 2024-07-16 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞

Country Status (29)

Country Link
US (3) US10316102B2 (OSRAM)
EP (2) EP3597742B1 (OSRAM)
JP (6) JP6161098B2 (OSRAM)
KR (1) KR101890638B1 (OSRAM)
CN (1) CN107109421B (OSRAM)
AU (1) AU2015329444B2 (OSRAM)
BR (1) BR112017006710B1 (OSRAM)
CA (1) CA2962375C (OSRAM)
CY (2) CY1122324T1 (OSRAM)
DK (2) DK3597742T3 (OSRAM)
ES (2) ES2751945T3 (OSRAM)
HR (2) HRP20221211T1 (OSRAM)
HU (2) HUE046710T2 (OSRAM)
IL (1) IL251504B (OSRAM)
LT (2) LT3205720T (OSRAM)
MX (1) MX358472B (OSRAM)
MY (1) MY167722A (OSRAM)
NZ (1) NZ730382A (OSRAM)
PH (1) PH12017500596B1 (OSRAM)
PL (2) PL3205720T3 (OSRAM)
PT (2) PT3205720T (OSRAM)
RS (2) RS63601B1 (OSRAM)
RU (1) RU2670147C1 (OSRAM)
SG (1) SG11201702391RA (OSRAM)
SI (2) SI3597742T1 (OSRAM)
SM (1) SMT201900663T1 (OSRAM)
TW (1) TWI688651B (OSRAM)
WO (1) WO2016056228A1 (OSRAM)
ZA (1) ZA201701968B (OSRAM)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3597742T3 (da) * 2014-10-09 2022-10-03 Univ Yamaguchi Car-udtrykkende vektor og car-udtrykkende t-celler
GB201509413D0 (en) * 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
CA3013479A1 (en) 2016-02-16 2017-08-24 Carl NOVINA Immunotherapy compositions and methods
AU2017235116B2 (en) * 2016-03-17 2019-11-07 Yamaguchi University Immunocompetent cell and expression vector expressing regulatory factors of immune function
WO2018119518A1 (en) * 2017-01-01 2018-07-05 Lee Chi Yu Gregory Rp215 chimeric antigen receptor construct and methods of making and using same
KR102564097B1 (ko) * 2017-01-10 2023-08-04 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 항 gpc3 항체
SG11201908659RA (en) 2017-03-27 2019-10-30 Noile Immune Biotech Inc Chimeric antigen receptor
CN108484777B (zh) * 2017-03-31 2022-07-12 李吉祐 人源化rp215单克隆抗体的嵌合抗原受体构建体及核酸分子与应用
EP3695846B1 (en) * 2017-10-10 2023-11-29 Yamaguchi University Enhancer for t-cells or b-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in t-cells or b-cells
FI3730612T3 (fi) * 2017-12-24 2026-04-30 Noile Immune Biotech Inc Immunokompetentti solu, joka ilmaisee erityisesti ihmisen mesoteliinin, il-7:n ja ccl19:n tunnistavan solukalvon molekyylin
MX2020006843A (es) 2017-12-27 2020-09-03 Takeda Pharmaceuticals Co Nanoparticula de lipido que contiene acido nucleico y uso de la misma.
CN108659133A (zh) * 2018-04-26 2018-10-16 上海怡豪生物科技有限公司 肺癌的双靶点car-t治疗载体及其构建方法和应用
CN108641001A (zh) * 2018-04-26 2018-10-12 上海怡豪生物科技有限公司 结肠癌的双靶点car-t治疗载体及其构建方法和应用
CN108641000A (zh) * 2018-04-26 2018-10-12 上海怡豪生物科技有限公司 肝癌的双靶点car-t治疗载体及其构建方法和应用
JP2021523743A (ja) * 2018-05-15 2021-09-09 カースゲン セラピューティクス カンパニー リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． 遺伝子操作された細胞及びその応用
KR20190141511A (ko) * 2018-06-14 2019-12-24 주식회사 녹십자랩셀 신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포
CN108866004A (zh) * 2018-06-26 2018-11-23 奥妙生物技术（广州）有限公司 Shp-1敲除的t细胞及其构建方法
WO2020006312A1 (en) 2018-06-28 2020-01-02 Dana-Farber Cancer Institute, Inc. Targeting of multiple antigens with multiplex car t cells in solid and liquid malignancies
CN112469829B (zh) * 2018-07-17 2023-07-07 诺伊尔免疫生物科技株式会社 包含抗gpc3单链抗体的car
CN109055430A (zh) * 2018-08-14 2018-12-21 杭州荣泽生物科技有限公司 一种共表达il18和ccl19蛋白及靶向muc1基因car-t细胞的制备方法
EP3845654A4 (en) * 2018-08-31 2022-05-11 Noile-Immune Biotech, Inc. Car-expressing t cells and car expression vector
US20210252069A1 (en) * 2018-09-05 2021-08-19 Seogkyoung KONG Chimeric antigen receptor for solid cancer and t cells expressing chimeric antigen receptor
US20220096544A1 (en) * 2018-09-20 2022-03-31 Cafa Therapeutics Limited Chemokine expressing cell and use thereof
US20210338729A1 (en) * 2018-10-12 2021-11-04 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF
CN109504660B (zh) * 2018-11-02 2021-08-06 温州启星生物技术有限公司 一种第四代car-t细胞及其构建方法和应用
US20220033848A1 (en) * 2018-11-19 2022-02-03 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
CN113543792A (zh) * 2019-03-08 2021-10-22 奥托路斯有限公司 包含工程化嵌合抗原受体和car调节剂的组合物和方法
JP7585228B2 (ja) * 2019-04-04 2024-11-18 上海医薬集団股▲フン▼有限公司 腫瘍抗原認識受容体を有する免疫細胞とその応用
CN112080526A (zh) * 2019-06-14 2020-12-15 南京艾德免疫治疗研究院有限公司 表达il-7和car的表达载体及免疫细胞
CN112080525A (zh) * 2019-06-14 2020-12-15 南京艾德免疫治疗研究院有限公司 一种改良型嵌合抗原受体t细胞的制备
JP7769325B2 (ja) * 2019-07-23 2025-11-13 株式会社東芝 Ｃａｒ－ｔ細胞の製造方法、核酸導入キャリア及びキット
US20220401480A1 (en) 2019-10-28 2022-12-22 Noile-Immune Biotech Inc. Drug for Treating Cancer, Combination Drug, Drug Composition, Immune Responsive Cell, Nucleic Acid Delivery Vehicle, and Product
CN110922490B (zh) * 2019-12-05 2023-03-03 浙江启新生物技术有限公司 分泌白介素7和趋化因子21的car表达载体及应用
KR20210103975A (ko) * 2020-02-14 2021-08-24 (주)이뮤노텍바이오팜코리아 외부에서 도입된 세포 신호 조절 인자를 과발현하는 면역 세포 및 이들의 용도
JP2021142156A (ja) * 2020-03-12 2021-09-24 株式会社三洋物産 遊技機
JP2021142158A (ja) * 2020-03-12 2021-09-24 株式会社三洋物産 遊技機
JP2021142159A (ja) * 2020-03-12 2021-09-24 株式会社三洋物産 遊技機
CN113528483B (zh) * 2020-04-22 2024-08-16 复星凯特生物科技有限公司 Shp2特异性失活突变蛋白及其在car-t治疗中应用
GB202006820D0 (en) * 2020-05-07 2020-06-24 Autolus Ltd Cell
EP4170020A4 (en) 2020-06-17 2025-01-22 Kyoto University IMMUNOCOMPETENT CELLS WITH CHIMERIC ANTIGEN RECEPTOR EXPRESSION
KR102297396B1 (ko) 2020-07-29 2021-09-06 (주)티카로스 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포
JP2023553157A (ja) 2020-12-10 2023-12-20 ユーティレックス カンパニー リミテッド 抗－ｐｄ－１抗体およびその用途
WO2022135357A1 (en) * 2020-12-22 2022-06-30 Sunshine Lake Pharma Co., Ltd. A hIL7/hCCL19 DOUBLE GENE RECOMBINANT ONCOLYTIC VIRUS AND ITS PREPARATION METHOD AND USE
CN114716548B (zh) 2021-01-05 2024-11-05 (株)爱恩德生物 抗-fgfr3抗体及其用途
CN112961248B (zh) * 2021-02-22 2022-03-18 广州百暨基因科技有限公司 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用
KR102568745B1 (ko) 2021-05-18 2023-08-24 주식회사 바이오솔루션 세포외소포체 분비능이 증진된 면역세포 및 이를 활용한 면역 항암요법
CN117642421A (zh) 2021-07-29 2024-03-01 武田药品工业株式会社 特异性靶向间皮素的工程化免疫细胞以及其用途
CN113913385A (zh) * 2021-09-01 2022-01-11 苏州璞惠卓越生物科技有限公司 一种抑制蛋白阻断型嵌合抗原受体修饰的免疫细胞及其用途
CN113921082B (zh) * 2021-10-27 2023-04-07 云舟生物科技(广州)股份有限公司 基因搜索权重调整方法、计算机存储介质及电子设备
US20250230215A1 (en) * 2021-11-08 2025-07-17 Memorial Sloan-Kettering Cancer Center Immune cells expressing glucose transporter 5 (glut5) and compositions and methods including the same
JP2025516892A (ja) * 2022-05-20 2025-05-30 武田薬品工業株式会社 操作された免疫細胞を産生する方法
US12006353B2 (en) 2022-07-25 2024-06-11 Long Chen Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof
AU2023313641A1 (en) 2022-07-26 2025-03-13 Aimed Bio Inc. Anti-ror1 antibody and use thereof
CN115505601B (zh) * 2022-10-17 2024-05-28 深圳市先康达生命科学有限公司 一种两级SynNotch逻辑调控结构及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5857318A (ja) * 1981-10-01 1983-04-05 Nippon Koutai Kenkyusho:Kk 癌細胞障害性リンパ球の製造法
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
KR101361416B1 (ko) 2008-10-08 2014-02-21 인트렉손 코포레이션 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3693017A1 (en) * 2010-12-14 2020-08-12 University of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
TR201815488T4 (tr) 2011-04-08 2018-11-21 Health Anti-epidermal büyüme faktör reseptörü varyant III kimerik antijen reseptörleri ve kanser tedavisi için kullanımı.
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
EP2755487B1 (en) * 2011-09-16 2018-12-19 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
WO2013051718A1 (ja) 2011-10-07 2013-04-11 国立大学法人三重大学 キメラ抗原受容体
EP3594245A1 (en) * 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
SG11201404284SA (en) 2012-02-22 2014-10-30 Univ Pennsylvania Use of the cd2 signaling domain in second-generation chimeric antigen receptors
CN102625373A (zh) * 2012-02-22 2012-08-01 中兴通讯股份有限公司 一种智能载波管理方法及装置
DK3597742T3 (da) * 2014-10-09 2022-10-03 Univ Yamaguchi Car-udtrykkende vektor og car-udtrykkende t-celler

Similar Documents

Publication Publication Date Title
Stork et al. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives
JP2019522054A5 (OSRAM)
Weiskopf et al. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies
JP2020506962A5 (OSRAM)
HRP20221211T1 (hr) Car-izražavajući vektor i t-stanice koje izražavaju car
JP2020108398A5 (OSRAM)
JP2021502104A5 (OSRAM)
JP2021522798A5 (OSRAM)
HRP20191800T1 (hr) Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti
JP2020517259A5 (OSRAM)
JP2021523192A5 (OSRAM)
Shiozawa et al. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells
HRP20240971T1 (hr) Polipeptidi za regruitiranje t-stanica na temelju cd3 reaktivnosti
JP2017513470A5 (OSRAM)
JP2023524047A5 (OSRAM)
JP2018512168A5 (OSRAM)
JP2021534740A5 (OSRAM)
JP2013227339A5 (OSRAM)
JP2023513156A5 (OSRAM)
JP2023520773A5 (OSRAM)
Vo et al. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?
JP2008502314A (ja) 治療および診断用抗Ｈｓｐ７０抗体
JP2023514148A5 (OSRAM)
Ubukata et al. Establishment of a Highly-Sensitive and Specific anti-EphB2 Monoclonal Antibody Eb2Mab-12 for Flow Cytometry
Anderson et al. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting